| Authors: |
Whalley D; From the RTI Health Solutions, Patient-Centered Outcomes Assessment, Manchester, United Kingdom., Balp MM; Novartis Pharma AG, HEOR International, Basel, Switzerland., Naujoks C; Novartis Pharma AG, HEOR International, Basel, Switzerland., Gardner DD; Allergy and Asthma Network, Fairfax, Virginia., Dery E; Canadian Chronic Urticaria Society, Quebec City, Canada., Weller K; Institute of Allergology, Charité -Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Van Der Poel LA; Children's Allergy Service, The Medical Chambers, Kensington London, United Kingdom., Erlewyn-Lajeunesse M; Children's Allergy Clinic, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom; and., Soong W; Allervie Health, Birmingham, Alabama, Virginia. |